Martinez Marina C, Finegersh Andrey, Baik Fred M, Holsinger F Chris, Starmer Heather M, Orloff Lisa A, Sunwoo John B, Sirjani Davud, Divi Vasu, Chen Michelle M
Stanford University School of Medicine, Palo Alto, California.
Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Palo Alto, California.
JAMA Otolaryngol Head Neck Surg. 2024 Dec 1;150(12):1097-1104. doi: 10.1001/jamaoto.2024.3233.
Depression is more prevalent among individuals with cancer than in the general population and is correlated with increased mortality in patients with head and neck cancer (HNC) in particular.
To compare the prevalence of depression between patients with HNC and patients with other cancers.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used population-level data on patients aged 18 years or older with cancer who participated in the 2019 National Health Interview Survey and had completed the Personal Health Questionnaire-8 (PHQ-8). The analysis was performed between August 7, 2023, and April 5, 2024.
Any cancer diagnosis.
The main outcome was prevalence and severity of depression based on the PHQ-8. The magnitude of the difference in baseline characteristics was measured between patients with HNC and those with other cancer types, and 95% CIs were used to measure the precision of these estimates. Multivariable logistic regressions were used to evaluate the association of demographic, socioeconomic, anxiety, and clinical variables with depression.
From a weighted cohort of 23 496 725 adult patients with cancer, 377 080 were diagnosed with HNC (87.5% aged 51-84 years; 77.9% male). The prevalence of any depression on the PHQ-8 (mild, moderate, or severe) was 40.1% in patients with HNC vs 22.3% in patients with other cancers. Compared with patients with other cancers, patients with HNC were equally likely to screen positive for anxiety (23.6% vs 16.0%; difference, 7.6%; 95% CI, -5.9% to 21.1%), take medication for depression (10.1% vs 13.9%; difference, -3.8%; 95% CI, -11.9% to 4.4%), and state that they never feel depressed (59.7% vs 53.7%; difference, 6.0%; 95% CI, -9.1% to 21.0%). On multivariable logistic regression analysis, having HNC was associated with an increased likelihood of depression (odds ratio [OR], 2.94; 95% CI, 1.39-6.22). Other factors associated with depression were being unmarried or not living with a partner (OR, 1.94; 95% CI, 1.55-2.43) and having anxiety (OR, 23.14; 95% CI, 17.62-30.37).
This cohort study found that patients with HNC were twice as likely to screen positive for depression on a validated survey than those with other cancers, despite having similar rates of self-reported depression and depression medication use. These findings suggest that self-reporting of depression may result in underreporting and undertreatment in this population and, thus, a need for further work in developing interventions to improve identification of and optimize treatment for patients with HNC and comorbid depression.
抑郁症在癌症患者中比在普通人群中更为普遍,尤其与头颈癌(HNC)患者的死亡率增加相关。
比较HNC患者与其他癌症患者中抑郁症的患病率。
设计、设置和参与者:这项回顾性队列研究使用了2019年全国健康访谈调查中18岁及以上癌症患者的人群水平数据,这些患者完成了个人健康问卷-8(PHQ-8)。分析于2023年8月7日至2024年4月5日进行。
任何癌症诊断。
主要结局是基于PHQ-8的抑郁症患病率和严重程度。测量了HNC患者与其他癌症类型患者基线特征差异的大小,并使用95%置信区间来衡量这些估计的精度。多变量逻辑回归用于评估人口统计学、社会经济、焦虑和临床变量与抑郁症的关联。
在加权后的23496725名成年癌症患者队列中,377080人被诊断为HNC(87.5%年龄在51 - 84岁;77.9%为男性)。PHQ-8上任何程度抑郁症(轻度、中度或重度)的患病率在HNC患者中为4%,在其他癌症患者中为22.3%。与其他癌症患者相比,HNC患者焦虑筛查呈阳性的可能性相同(23.6%对16.0%;差异7.6%;95%置信区间,-5.9%至21.1%),服用抗抑郁药物的可能性相同(10.1%对13.9%;差异-3.8%;95%置信区间,-11.9%至4.4%),且表示从未感到抑郁的可能性相同(59.7%对53.7%;差异6.0%;95%置信区间,-9.1%至21.0%)。在多变量逻辑回归分析中,患有HNC与抑郁症可能性增加相关(比值比[OR],2.94;95%置信区间,1.39 - 6.22)。与抑郁症相关的其他因素包括未婚或未与伴侣同住(OR,1.94;95%置信区间,1.55 - 2.43)以及患有焦虑症(OR,23.14;95%置信区间,17.62 - 30.37)。
这项队列研究发现,尽管自我报告的抑郁症和使用抗抑郁药物的比例相似,但在经过验证的调查中,HNC患者抑郁症筛查呈阳性的可能性是其他癌症患者的两倍。这些发现表明,在该人群中抑郁症的自我报告可能导致报告不足和治疗不足,因此需要进一步开展工作,开发干预措施以改善HNC合并抑郁症患者的识别和优化治疗。